Federal Cannabis Laws Explained: Where Rescheduling and Reform Stand

## The Short Answer Federal law treats cannabis as a Schedule I controlled substance under the Controlled Substances Act of 1970, meaning the federal government classifies it as having no accepted medical use and high abuse potential. Adult-use and medical cannabis operate at the state level under a complicated patchwork of federal non-enforcement guidance. For adults 21 and older in legal states, this produces a strange overlap: legal under state law, illegal under federal law. ## Schedule I The Controlled Substances Act (CSA) places drugs into five schedules. Schedule I is the most restrictive and reserved for substances deemed: - To have high abuse potential. - To have no accepted medical use. - To lack accepted safety even under medical supervision. Cannabis has been in Schedule I since 1970. Rescheduling would require either congressional action or agency action by the DEA following HHS recommendations. ## The Rescheduling Conversation In 2023, HHS recommended cannabis be rescheduled to Schedule III (less restrictive, recognizing medical use). The DEA initiated a formal rulemaking process. As of early 2026, the rulemaking has advanced through various stages of review, and the outcome remains subject to administrative process and legal challenge. Schedule III rescheduling would not legalize cannabis federally. It would modify tax treatment (eliminating 280E, which prevents cannabis businesses from deducting ordinary business expenses from federal taxes), potentially ease research restrictions, and signal federal acknowledgment of medical use. It would not decriminalize possession or legalize interstate commerce. ## De Facto State-Level Legality The federal government has largely not enforced the CSA against state-compliant cannabis businesses since: - **Cole Memo (2013)** guided federal prosecutors to not prioritize state-legal cannabis businesses (rescinded 2018, but practices largely persisted). - **Appropriations rider (2014-present)** prohibits DOJ from spending funds to interfere with state medical cannabis programs. Federal non-enforcement is policy, not statute. A different administration or DOJ leadership could change enforcement posture. ## Consequences of Federal Illegality Even with state-level legality, federal Schedule I status produces: - **Banking difficulties.** Federally-regulated banks struggle to serve cannabis businesses, forcing cash-heavy operations. - **Tax disadvantages.** IRC 280E prevents cannabis businesses from deducting ordinary business expenses. - **Research restrictions.** Schedule I complicates clinical research. - **Professional licensing conflicts.** Federal employees, military personnel, and certain licensed professionals (medicine, law) face conflicts. - **Immigration consequences.** Cannabis use, even in state-legal contexts, can create immigration and naturalization problems. - **Interstate commerce prohibition.** Cannabis cannot legally cross state lines. ## The SAFE Banking Act The Secure and Fair Enforcement (SAFE) Banking Act, or its variants, has been introduced in multiple Congresses to address the banking issue. As of early 2026, it has not been signed into law. ## Where to Go Next Related reading: [is cannabis legal in my state](/blog/is-cannabis-legal-in-my-state-a-state-by-state-guide-to-marijuana-laws), [cannabis banking and the SAFE Act](/blog/cannabis-banking-and-the-safe-act-why-it-matters-for-the-industry), and [hemp vs marijuana legal definitions](/blog/hemp-vs-marijuana-legal-definitions-and-why-they-matter). --- *This article is consumer education for adults 21+. Nothing here is medical, legal, or financial advice. Cannabis laws vary by state, always verify your state's current rules and, for health questions, consult a licensed clinician. For regulated New York retail, verify licensing via the OCM QR-code system at [cannabis.ny.gov](https://cannabis.ny.gov).*